UKUK

Chroma signs huge deal with GSK

14.07.2009

Abingdon/London – Biotech platform technologies apparently still matter. An advanced technology platform could now end up bringing US$1bn to British drug developer Chroma Therapeutics Ltd. At the end of June, the Abingdon-based biotech company inked a collaboration agreement with pharma giant GlaxoSmithKline (GSK) to develop macrophage-targeted compounds using Chroma’s esterase-sensitive motif (ESM) technology. The technology is designed to target compounds in the cytoplasm of specific cells by coupling them to certain amino acid esters that are cleaved inside the cell, leaving a charged molecule incapable of leaking out of the cell. The approach could bring advantages in treatments for inflammatory diseases by increasing the therapeutic window when compared to the “parent” drug, and reducing systemic exposure outside of the macrophages. Chroma has already applied the technology to a number of key inflammation targets such as P38 MAP Kinase, PI-3 Kinase, IKK-beta and PDE4.
Under the terms of the collaboration with GSK’s Centre of Excellence for External Drug Discovery (CEEDD) in Stevenage (UK), Chroma will undertake four programmes to identify small molecule therapeutics, including a macrophage-targeted HDAC inhibitor programme for inflammatory disorders such as RA.
GSK announced that Chroma will receive a significant up-front cash payment, and that GSK will participate in Chroma’s recent EUR17.5m equity financing. Additionally, Chroma is to receive milestones, option fees and tiered royalties based on compounds arising from the collaboration. The deal could total up to US$1bn in case of clinical proof-of-concept in all programmes.
GSK may elect to obtain an exclusive, worldwide license to product candidates within the programme. At such time GSK will assume full responsibility for development and commercialisation. Chroma will retain full rights to further develop and commercialise its product candidates in any programme GSK chooses not to license.
“We believe Chroma’s ESM platform has tremendous potential,” stated Shelagh Wilson, Vice President and Head of the European CEEDD, while Chroma’s CEO Ian Nicholson said the collaboration was a strong validation of his company’s cell accumulation approach.

UKUK

02.04.2012

London - The not-for-profit UK Biobank, the most comprehensive health study in Britain, is now accessible to researchers from industry and academia. The resource, which contains some 1,000 pieces of health and lifestyle...

UKUK

21.03.2012

London – The British Wellcome Trust announced on 20 March that it will launch a £200m business to invest directly in healthcare and life sciences companies. The business, up to now running under its working title Project Sigma,...

UKUK

07.03.2012

Nanopore sequencer Oxford Nanopore Technologies, a UK firm that promises its third-generation technology could theoretically sequence a human genome in 15 minutes, impressed scientists with the first public presentation of its...

UKUK

06.03.2012

GlaxoSmithKline (GSK) is further strengthening its activity in the area of rare diseases. The London-based pharma giant has signed an early-stage deal to develop and commercialise treatments for lysosomal storage disorders...

UKUK

27.02.2012

London/Montreal - Angiochem will collaborate with British pharma trust GlaxoSmithKline (GSK) plc on treatments for lysosomal storage diseases (LSD). London-based GSK will pay $300m, including up to $31.5m in upfront cash and...

UKUK

08.02.2012

London - GlaxoSmithKline re-adjusts its €3.7bn R&D budget. Following a review, three of 38 R&D units will be cut and four new ones installed, the UK drug company said in a statement on 7 Februray. Furthermore, six of the...

UKUK

03.02.2012

London - AstraZeneca tries to shed some weight, anticipating a tough year ahead. 7,300 jobs will be gone soon, the Anglo-Swedish drug company said in a statement. Research and development operations will be cancelled in...

UKUK

16.01.2012

Newhouse – An example of Schumpeter's dictum of creative destruction can be witnessed in Scotland. A former research site of US-pharma company Merck will be reborn as a biotech science park. BioCity Scotland Ltd, a joint venture...

Displaying results 1 to 10 out of 396

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-uk/article/chroma-signs-huge-deal-with-gsk.html

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR310.5%
  • SANTHERA (CH)69.30 CHF132.6%
  • ADDEX (CH)4.07 CHF89.3%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • THROMBOGENICS (B)8.87 EUR-38.3%
  • HYBRIGENICS (F)1.72 EUR-34.1%

TOP

  • SANTHERA (CH)69.30 CHF3365.0%
  • GW PHARMACEUTICALS (UK)438.00 GBP812.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.7%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.1%

No liability assumed, Date: 22.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events